Shopping Cart 0
Cart Subtotal
AED 0

Osteoporosis - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Osteoporosis-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis-Pipeline Review, H2 2018, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 1, 6, 4, 21, 3, 56, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 12 and 12 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 6

Osteoporosis-Overview 7

Osteoporosis-Therapeutics Development 8

Osteoporosis-Therapeutics Assessment 25

Osteoporosis-Companies Involved in Therapeutics Development 35

Osteoporosis-Drug Profiles 66

Osteoporosis-Dormant Projects 239

Osteoporosis-Discontinued Products 247

Osteoporosis-Product Development Milestones 249

Appendix 258


List Of Figure

List of Figures

Number of Products under Development for Osteoporosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Osteoporosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Osteoporosis-Pipeline by Abreos Biosciences Inc, H2 2018

Osteoporosis-Pipeline by Alvogen Korea Co Ltd, H2 2018

Osteoporosis-Pipeline by Amgen Inc, H2 2018

Osteoporosis-Pipeline by Asahi Kasei Corp, H2 2018

Osteoporosis-Pipeline by BiosanaPharma BV, H2 2018

Osteoporosis-Pipeline by Biosion Inc, H2 2018

Osteoporosis-Pipeline by Bone Biologics Corp, H2 2018

Osteoporosis-Pipeline by Bristol-Myers Squibb Co, H2 2018

Osteoporosis-Pipeline by Cadila Healthcare Ltd, H2 2018

Osteoporosis-Pipeline by ChoDang Pharm Co Ltd, H2 2018

Osteoporosis-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Osteoporosis-Pipeline by Corium International Inc, H2 2018

Osteoporosis-Pipeline by Daewon Pharm Co Ltd, H2 2018

Osteoporosis-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Osteoporosis-Pipeline by Dong Wha Pharma Co Ltd, H2 2018

Osteoporosis-Pipeline by Eli Lilly and Co, H2 2018

Osteoporosis-Pipeline by EndoCeutics Inc, H2 2018

Osteoporosis-Pipeline by Entera Bio Ltd, H2 2018

Osteoporosis-Pipeline by Enteris BioPharma Inc, H2 2018

Osteoporosis-Pipeline by Enzene Biosciences Ltd, H2 2018

Osteoporosis-Pipeline by Enzo Biochem Inc, H2 2018

Osteoporosis-Pipeline by Evgen Pharma Plc, H2 2018

Osteoporosis-Pipeline by Gador SA, H2 2018

Osteoporosis-Pipeline by Genor BioPharma Co Ltd, H2 2018

Osteoporosis-Pipeline by GL Pharm Tech Corp, H2 2018

Osteoporosis-Pipeline by GlycoNex Inc, H2 2018

Osteoporosis-Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018

Osteoporosis-Pipeline by Haoma Medica Ltd, H2 2018

Osteoporosis-Pipeline by Huons Global Co Ltd, H2 2018

Osteoporosis-Pipeline by Immunwork Inc, H2 2018

Osteoporosis-Pipeline by Innovent Biologics Inc, H2 2018

Osteoporosis-Pipeline by InSight Biopharmaceuticals Ltd, H2 2018

Osteoporosis-Pipeline by Intas Pharmaceuticals Ltd, H2 2018

Osteoporosis-Pipeline by Ipsen SA, H2 2018

Osteoporosis-Pipeline by JHL Biotech Inc, H2 2018

Osteoporosis-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Osteoporosis-Pipeline by Lead Discovery Center GmbH, H2 2018

Osteoporosis-Pipeline by Lotus Pharmaceutical Co Ltd, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Osteoporosis Therapeutic Products under Development, Key Players in Osteoporosis Therapeutics, Osteoporosis Pipeline Overview, Osteoporosis Pipeline, Osteoporosis Pipeline Assessment


Companies

Abreos Biosciences Inc

Alvogen Korea Co Ltd

Amgen Inc

Asahi Kasei Corp

BiosanaPharma BV

Biosion Inc

Bone Biologics Corp

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

ChoDang Pharm Co Ltd

Chugai Pharmaceutical Co Ltd

Corium International Inc

Daewon Pharm Co Ltd

Daiichi Sankyo Co Ltd

Dong Wha Pharma Co Ltd

Eli Lilly and Co

EndoCeutics Inc

Entera Bio Ltd

Enteris BioPharma Inc

Enzene Biosciences Ltd

Enzo Biochem Inc

Evgen Pharma Plc

Gador SA

Genor BioPharma Co Ltd

GL Pharm Tech Corp

GlycoNex Inc

Hanmi Pharmaceuticals Co Ltd

Haoma Medica Ltd

Huons Global Co Ltd

Immunwork Inc

Innovent Biologics Inc

InSight Biopharmaceuticals Ltd

Intas Pharmaceuticals Ltd

Ipsen SA

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Lead Discovery Center GmbH

Lotus Pharmaceutical Co Ltd

Lupin Ltd

Luye Pharma Group Ltd

mAbxience SA

Merck & Co Inc

Millendo Therapeutics Inc

Nano Intelligent Biomedical Engineering Corp

Omeros Corp

Oncobiologics Inc

Paras Biopharmaceuticals Finland Oy

Pfenex Inc

PhytoHealth Corp

R Pharm

Reliance Life Sciences Pvt Ltd

Ribomic Inc

Richter Gedeon Nyrt

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Shin Poong PharmCo Ltd

Sinil Pharmaceutical Co Ltd

Stelis Biopharma Pvt Ltd

Terpenoid Therapeutics Inc

TSH Biopharm Corporation Ltd

Uni-Bio Science Group Ltd

Viking Therapeutics Inc

ViroMed Co Ltd

Wroclawskie Centrum Badan EIT+ Sp z oo

Yooyoung Pharm Co Ltd

Osteoporosis-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis-Pipeline Review, H2 2018, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 1, 6, 4, 21, 3, 56, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 12 and 12 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 6

Osteoporosis-Overview 7

Osteoporosis-Therapeutics Development 8

Osteoporosis-Therapeutics Assessment 25

Osteoporosis-Companies Involved in Therapeutics Development 35

Osteoporosis-Drug Profiles 66

Osteoporosis-Dormant Projects 239

Osteoporosis-Discontinued Products 247

Osteoporosis-Product Development Milestones 249

Appendix 258


List Of Figure

List of Figures

Number of Products under Development for Osteoporosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Osteoporosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Osteoporosis-Pipeline by Abreos Biosciences Inc, H2 2018

Osteoporosis-Pipeline by Alvogen Korea Co Ltd, H2 2018

Osteoporosis-Pipeline by Amgen Inc, H2 2018

Osteoporosis-Pipeline by Asahi Kasei Corp, H2 2018

Osteoporosis-Pipeline by BiosanaPharma BV, H2 2018

Osteoporosis-Pipeline by Biosion Inc, H2 2018

Osteoporosis-Pipeline by Bone Biologics Corp, H2 2018

Osteoporosis-Pipeline by Bristol-Myers Squibb Co, H2 2018

Osteoporosis-Pipeline by Cadila Healthcare Ltd, H2 2018

Osteoporosis-Pipeline by ChoDang Pharm Co Ltd, H2 2018

Osteoporosis-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Osteoporosis-Pipeline by Corium International Inc, H2 2018

Osteoporosis-Pipeline by Daewon Pharm Co Ltd, H2 2018

Osteoporosis-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Osteoporosis-Pipeline by Dong Wha Pharma Co Ltd, H2 2018

Osteoporosis-Pipeline by Eli Lilly and Co, H2 2018

Osteoporosis-Pipeline by EndoCeutics Inc, H2 2018

Osteoporosis-Pipeline by Entera Bio Ltd, H2 2018

Osteoporosis-Pipeline by Enteris BioPharma Inc, H2 2018

Osteoporosis-Pipeline by Enzene Biosciences Ltd, H2 2018

Osteoporosis-Pipeline by Enzo Biochem Inc, H2 2018

Osteoporosis-Pipeline by Evgen Pharma Plc, H2 2018

Osteoporosis-Pipeline by Gador SA, H2 2018

Osteoporosis-Pipeline by Genor BioPharma Co Ltd, H2 2018

Osteoporosis-Pipeline by GL Pharm Tech Corp, H2 2018

Osteoporosis-Pipeline by GlycoNex Inc, H2 2018

Osteoporosis-Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018

Osteoporosis-Pipeline by Haoma Medica Ltd, H2 2018

Osteoporosis-Pipeline by Huons Global Co Ltd, H2 2018

Osteoporosis-Pipeline by Immunwork Inc, H2 2018

Osteoporosis-Pipeline by Innovent Biologics Inc, H2 2018

Osteoporosis-Pipeline by InSight Biopharmaceuticals Ltd, H2 2018

Osteoporosis-Pipeline by Intas Pharmaceuticals Ltd, H2 2018

Osteoporosis-Pipeline by Ipsen SA, H2 2018

Osteoporosis-Pipeline by JHL Biotech Inc, H2 2018

Osteoporosis-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Osteoporosis-Pipeline by Lead Discovery Center GmbH, H2 2018

Osteoporosis-Pipeline by Lotus Pharmaceutical Co Ltd, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Osteoporosis Therapeutic Products under Development, Key Players in Osteoporosis Therapeutics, Osteoporosis Pipeline Overview, Osteoporosis Pipeline, Osteoporosis Pipeline Assessment


Companies

Abreos Biosciences Inc

Alvogen Korea Co Ltd

Amgen Inc

Asahi Kasei Corp

BiosanaPharma BV

Biosion Inc

Bone Biologics Corp

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

ChoDang Pharm Co Ltd

Chugai Pharmaceutical Co Ltd

Corium International Inc

Daewon Pharm Co Ltd

Daiichi Sankyo Co Ltd

Dong Wha Pharma Co Ltd

Eli Lilly and Co

EndoCeutics Inc

Entera Bio Ltd

Enteris BioPharma Inc

Enzene Biosciences Ltd

Enzo Biochem Inc

Evgen Pharma Plc

Gador SA

Genor BioPharma Co Ltd

GL Pharm Tech Corp

GlycoNex Inc

Hanmi Pharmaceuticals Co Ltd

Haoma Medica Ltd

Huons Global Co Ltd

Immunwork Inc

Innovent Biologics Inc

InSight Biopharmaceuticals Ltd

Intas Pharmaceuticals Ltd

Ipsen SA

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Lead Discovery Center GmbH

Lotus Pharmaceutical Co Ltd

Lupin Ltd

Luye Pharma Group Ltd

mAbxience SA

Merck & Co Inc

Millendo Therapeutics Inc

Nano Intelligent Biomedical Engineering Corp

Omeros Corp

Oncobiologics Inc

Paras Biopharmaceuticals Finland Oy

Pfenex Inc

PhytoHealth Corp

R Pharm

Reliance Life Sciences Pvt Ltd

Ribomic Inc

Richter Gedeon Nyrt

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Shin Poong PharmCo Ltd

Sinil Pharmaceutical Co Ltd

Stelis Biopharma Pvt Ltd

Terpenoid Therapeutics Inc

TSH Biopharm Corporation Ltd

Uni-Bio Science Group Ltd

Viking Therapeutics Inc

ViroMed Co Ltd

Wroclawskie Centrum Badan EIT+ Sp z oo

Yooyoung Pharm Co Ltd